AR034887A1 - Medicamento inhibidor del sistema de intercambio sodio/calcio - Google Patents
Medicamento inhibidor del sistema de intercambio sodio/calcioInfo
- Publication number
- AR034887A1 AR034887A1 ARP020102779A ARP020102779A AR034887A1 AR 034887 A1 AR034887 A1 AR 034887A1 AR P020102779 A ARP020102779 A AR P020102779A AR P020102779 A ARP020102779 A AR P020102779A AR 034887 A1 AR034887 A1 AR 034887A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- sodium
- exchange system
- calcium
- calcium exchange
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 3
- 239000011575 calcium Substances 0.000 title abstract 3
- 229910052791 calcium Inorganic materials 0.000 title abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- CBXCENINGXRLJX-UHFFFAOYSA-N 2-piperazin-1-yl-5-(trifluoromethyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1N1CCNCC1 CBXCENINGXRLJX-UHFFFAOYSA-N 0.000 abstract 1
- ZAJAQTYSTDTMCU-UHFFFAOYSA-N 3-aminobenzenesulfonic acid Chemical compound NC1=CC=CC(S(O)(=O)=O)=C1 ZAJAQTYSTDTMCU-UHFFFAOYSA-N 0.000 abstract 1
- DCDFLGVJWQIRGH-UHFFFAOYSA-N 5-methyl-2-piperazin-4-ium-1-ylbenzenesulfonate Chemical compound OS(=O)(=O)C1=CC(C)=CC=C1N1CCNCC1 DCDFLGVJWQIRGH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Urology & Nephrology (AREA)
Abstract
Medicamento inhibidor del sistema de intercambio sodio/calcio comprendiendo un ingrediente activo derivado del ácido aminobencensulfónico de fórmula (1) donde R1 es H, alquilo C1-6, cicloalquilo C3-7, haloalquilo C1-4, halógeno, arilo C6-12; R2 es H, alquilo C1-6, aralquilo C7-12 sustituido con ciano, nitro, halógeno, alquilo C1-6 o amino y n es 1 a 4, así como sales, hidratos o solvatos del mismo, junto con vehículos y aditivos. Es útil para prevenir o tratar la disfunción severa discrásica, resultante de isquemia/reperfusión, deteniendo el aumento de calcio en miocardio, por administración oral o parental. Ejemplos son ácido 5-metil-2-(1-piperazinil) bencensulfónico, ácido 5-trifluorometil-2-(1-piperazinil) bencensulfónico y otros descriptos en la Memoria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001224916 | 2001-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034887A1 true AR034887A1 (es) | 2004-03-24 |
Family
ID=19057997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102779A AR034887A1 (es) | 2001-07-25 | 2002-07-24 | Medicamento inhibidor del sistema de intercambio sodio/calcio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040259861A1 (es) |
| EP (1) | EP1409080A1 (es) |
| JP (1) | JP2004538292A (es) |
| KR (1) | KR20040028916A (es) |
| CN (1) | CN100502861C (es) |
| AR (1) | AR034887A1 (es) |
| CA (1) | CA2454681A1 (es) |
| PE (1) | PE20030278A1 (es) |
| WO (1) | WO2003009897A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003261815A1 (en) * | 2002-08-30 | 2004-03-19 | Mitsubishi Pharma Corporation | Inhibitors for excessive accumulation of sodium ion in cells |
| AU2003261968A1 (en) * | 2002-09-06 | 2004-03-29 | Mitsubishi Pharma Corporation | Protective agents for transplanted organ |
| WO2008010566A1 (fr) * | 2006-07-21 | 2008-01-24 | Mitsubishi Tanabe Pharma Corporation | Polymorphisme cristallin de l'acide 5-méthyl-2-(pipérazin-1-yl)-benzènesulfonique |
| JPWO2008010567A1 (ja) * | 2006-07-21 | 2009-12-17 | 田辺三菱製薬株式会社 | ５−メチル‐２‐（ピペラジン−１−イル）ベンゼンスルホン酸の塩形態又は溶媒和物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0686438B2 (ja) * | 1989-03-27 | 1994-11-02 | 三菱化成株式会社 | アミノベンゼンスルホン酸誘導体 |
| JP3083544B2 (ja) * | 1990-09-27 | 2000-09-04 | 三菱化学株式会社 | 心疾患を予防または治療する薬剤 |
| CA2192731C (en) * | 1995-12-15 | 2005-09-27 | Chika Yamazaki | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof |
| JP3215338B2 (ja) * | 1995-12-15 | 2001-10-02 | 三菱化学株式会社 | アミノベンゼンスルホン酸誘導体一水和物及びその製造方法 |
| JPH10298077A (ja) * | 1997-04-24 | 1998-11-10 | Mitsubishi Chem Corp | 心筋症の治療、予防剤 |
| WO1999040919A1 (fr) * | 1998-02-12 | 1999-08-19 | Mitsubishi Chemical Corporation | Medicaments contre les troubles diastoliques cardiaques |
| WO2001045739A1 (fr) * | 1999-12-21 | 2001-06-28 | Mitsubishi Pharma Corporation | Remedes et/ou medicaments preventifs pour troubles du systeme nerveux |
-
2002
- 2002-07-24 PE PE2002000650A patent/PE20030278A1/es not_active Application Discontinuation
- 2002-07-24 CN CNB028145305A patent/CN100502861C/zh not_active Expired - Fee Related
- 2002-07-24 AR ARP020102779A patent/AR034887A1/es not_active Application Discontinuation
- 2002-07-24 EP EP02755639A patent/EP1409080A1/en not_active Withdrawn
- 2002-07-24 KR KR10-2004-7000361A patent/KR20040028916A/ko not_active Application Discontinuation
- 2002-07-24 CA CA002454681A patent/CA2454681A1/en not_active Abandoned
- 2002-07-24 US US10/484,463 patent/US20040259861A1/en not_active Abandoned
- 2002-07-24 JP JP2003515287A patent/JP2004538292A/ja active Pending
- 2002-07-24 WO PCT/JP2002/007486 patent/WO2003009897A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003009897A1 (en) | 2003-02-06 |
| EP1409080A1 (en) | 2004-04-21 |
| CA2454681A1 (en) | 2003-02-06 |
| JP2004538292A (ja) | 2004-12-24 |
| KR20040028916A (ko) | 2004-04-03 |
| CN1533292A (zh) | 2004-09-29 |
| CN100502861C (zh) | 2009-06-24 |
| PE20030278A1 (es) | 2003-04-10 |
| US20040259861A1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656793T3 (es) | Salicilatos acetilados de ácidos grasos y sus usos | |
| PE20011001A1 (es) | Compuestos heterociclicos como inhibidores del intercambio de sodio/protones | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| ATE369370T1 (de) | Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren | |
| CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
| DOP2010000143A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| CO6160301A2 (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
| PE20121157A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
| PE20100737A1 (es) | Nuevos compuestos | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
| GT200100148A (es) | Derivados de 4-fenil-piridina. | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR053345A1 (es) | Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их | |
| AR029005A1 (es) | FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA | |
| GT200100251A (es) | Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida | |
| EA200501530A1 (ru) | Новые соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат | |
| AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
| AR034887A1 (es) | Medicamento inhibidor del sistema de intercambio sodio/calcio | |
| AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar | |
| AR054220A1 (es) | 5-fenilpirimidinas i sustituidas, composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |